Methyldopa Interactions

Brand names: Methyldopa

Route: Oral

Contraindications

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors.

Pregnancy & Breastfeeding

Pregnancy Teratogenic Effects . Reproduction studies performed with methyldopa at oral doses up to 1000 mg/kg in mice, 200 mg/kg in rabbits and 100 mg/kg in rats revealed no evidence of harm to the fetus. These doses are 16.6 times, 3.3 times and 1.7 times, respectively, the maximum daily human dose when compared on the basis of body weight; 1.4 times, 1.1 times and 0.2 times, respectively, when compared on the basis of body surface area; calculations assume a patient weight of 50 kg. There are, however, no adequate and well-controlled studies in pregnant women in the first trimester of pregnancy. Because animal reproduction studies are not always predictive of human response, methyldopa should be used during pregnancy only if clearly needed. Published reports of the use of methyldopa during all trimesters indicate that if this drug is used during pregnancy the possibility of fetal harm appears remote. In five studies, three of which were controlled, involving 332 pregnant hypertensive women, treatment with methyldopa was associated with an improved fetal outcome. The majority of these women were in the third trimester when methyldopa therapy was begun. In one study, women who had begun methyldopa treatment between weeks 16 and 20 of pregnancy gave birth to infants whose average head circumference was reduced by a small amount (34.2 ± 1.7 cm vs. 34.6 ± 1.3 cm [mean ± 1 S.D.]). Long-term follow-up of 195 (97.5%) of the children born to methyldopa-treated pregnant women (including those who began treatment between weeks 16 and 20) failed to uncover any significant adverse effect on the children. At 4 years of age, the developmental delay commonly seen in children born to hypertensive mothers was less evident in those whose mothers were treated with methyldopa during pregnancy than those whose mothers were untreated. The children of the treated group scored consistently higher than the children of the untreated group on five major indices of intellectual and motor deve

15 interactions on record

Methyldopa + LithiumModerate

Concomitant use may increase risk of adverse reactions of methyldopa.

Source: NLP:lithium

Methyldopa + Lithium CitrateModerate

Concomitant use may increase risk of adverse reactions of methyldopa. Monitor patients closely for adverse reactions.

Source: NLP:lithium citrate

Methyldopa + RiluzoleModerate

Hepatotoxic drug; riluzole-treated patients taking this may have increased risk for hepatotoxicity.

Source: NLP:riluzole

Methyldopa + TolcaponeModerate

Tolcapone may influence pharmacokinetics of COMT substrates like α-methyldopa. Dose reduction should be considered when co-administered.

Source: NLP:tolcapone

Methyldopa + VasopressinModerate

Suspected of causing SIADH; may increase pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended.

Source: NLP:vasopressin

Methyldopa + Vasopressin In 0.9% Sodium ChlorideModerate

May cause SIADH, increasing pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended; adjust vasopressin dose as needed.

Source: NLP:vasopressin in 0.9% sodium chloride

Methyldopa + Enalapril MaleateMinor

Used concomitantly with enalapril maleate without evidence of clinically significant adverse interactions.

Source: NLP:enalapril maleate

Methyldopa + RopiniroleMinor

Coadministration had no effect on steady-state pharmacokinetics of ropinirole; ropinirole increased mean steady-state Cmax of L-dopa by 20%.

Source: NLP:ropinirole